Notably, compared with the serum AFP < 20 ng/ml group, 10 (13.5%) patients were diagnosed with hepatoid adenocarcinoma in the AFP ≥ 20 ng/ml group. This evidence concerns the gene AFP and hepatoid adenocarcinoma.